Latest Health News

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.

Echo IQ has formally lodged its FDA 510(k) submission for EchoSolv HF, an AI-driven heart failure diagnostic software validated by Mayo Clinic data, aiming to tap into a $60 billion US market.

Apiam Animal Health Limited shareholders are set to vote on a scheme of arrangement offering $0.87 cash per share or a mix of cash and unlisted scrip in a new holding company controlled by Adamantem Capital. The Independent Expert deems the cash offer fair and reasonable, while scrip options carry liquidity and minority risks.

Korab Resources Limited reported a positive cash flow for the December 2024 quarter, maintaining a strong liquidity position with funding to support its exploration activities for over 17 quarters.

Artrya Limited has begun generating fee-per-scan revenues from its Salix Coronary Plaque module at Tanner Health in the U.S., marking a key commercial milestone for the AI-powered cardiac imaging platform.

HITIQ has secured a prestigious grant from the Australian Sports Commission to enhance its PROTEQT™ brain health monitoring technology, positioning the company for wider adoption across elite and community sports.

MPR Australia Limited has been suspended from ASX trading following the disposal of its main undertaking, with the exchange citing insufficient ongoing operations to justify continued quotation.

Assetora Limited has resolved a recent receivership by fully settling its outstanding debt, bringing external administration to a close within a day.

Macquarie Group Limited has announced an ordinary dividend of AUD 1.6883 per security for its perpetual capital notes, payable in March 2026. The distribution features a partially franked yield reflecting current market interest rates.

EV Resources has cleared a key technical review of its Tecomatlán processing plant in Mexico, setting the stage for near-term antimony concentrate production and pilot testing for its Los Lirios project.

Emyria Limited is scaling up its Perth Empax clinic with increased therapist approvals and treatment rooms, setting the stage for broader national clinical growth next year.

APA Group has announced a modest 1.9% increase in its interim distribution to 27.5 cents per security for the half year ending December 2025, maintaining steady income growth for investors.